Tech Company Financing Transactions
Anocca Funding Round
Mellby Gard, AMF and Ramsbury invested in a $46 million funding round for Anocca. The financing closed on 8/19/2025.
Transaction Overview
Company Name
Announced On
8/19/2025
Transaction Type
Venture Equity
Amount
$46,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to drive the continued progress of VIDAR-1, its gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress its preclinical pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Forskargatan 20C
Södertälje, 151 36
SE
Södertälje, 151 36
SE
Phone
Website
Email Address
Overview
Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. Anocca's technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/19/2025: Eight Sleep venture capital transaction
Next: 8/19/2025: Kasa Living venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs